BioVentrix to Sponsor Symposium at EuroPCR 2014 Highlighting Less Invasive Transcatheter Treatment for Heart Failure
SAN RAMON, Calif., April 25, 2014 — BioVentrix, a pioneer of technologies and products for less invasive treatment of heart failure (HF), today announced that it will sponsor a symposium at the 2014 EuroPCR Congress in Paris entitled, “Transcatheter Treatment of Ischaemic Heart Failure: The Less Invasive Ventricular Enhancement™ (LIVE™) Procedure Using the Revivent™ Myocardial Anchoring System.”
Chairing the EuroPCR symposium will be Prof. Horst Sievert from the CardioVascular Center (Frankfurt, Germany), with presentations and commentary from leading European heart failure specialists including:
- Prof. Olaf Wendler, King’s College Hospital (London, UK): “The LIVE procedure: Technology and Techniques.”
- Prof. Helge Moellmann, Kerckhoff-Klinik (Bad Nauheim, Germany): “Revivent and Revivent-TC: Clinical results to date.”
- Prof. Petr Neuzil, Na Homolce Hospital (Prague, Czech Republic): “Clinical case reports and identifying the ideal patient candidate for the LIVE procedure.”
The BioVentrix symposium will take place at EuroPCR on May 21, 2014 from 12:30-13:30 in Room 353. To register for the symposium and to hear a two-minute preview from the chairman and other faculty please click here. In addition to the symposium, BioVentrix will exhibit the Company’s latest technology, the Revivent-TC™ Ventricular Enhancement System that utilizes a transcatheter approach for the treatment of heart failure, in stand number M42.
“There is a great need for better treatment options for heart failure patients, especially for ischemic patients who develop scarring following a myocardial infarction,” said David Schickling, vice president of sales and marketing for BioVentrix. “The purpose of the symposium is to create awareness among physicians about our LIVE procedure and to expand the use of the world’s only less invasive treatment approach that attacks the underlying cause of heart failure. The Revivent System enables treatment of more frail patients and improves their quality of life by reshaping the left ventricle, reducing wall stress, and decreasing excessive LV volume, all without the need for ventriculotomy or cardiopulmonary bypass.”
“We will also be presenting the early experience from our second-generation device, the Revivent-TC Ventricular Enhancement System, which uses a hybrid transcatheter-thoracoscopic approach and eliminates the need to open the patient’s chest,” continued Schickling. “We anticipate this therapy will bridge the profound gap between medical therapy and more invasive surgical interventions such as LVADs or heart transplants.”
About the Revivent System and the LIVE Procedure
Placement of the Revivent System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled toward one another, effectively excluding the scarred, and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent.[i] Presentation of recent scientific data indicates that in 92 percent of patients, the efficacy results were durable beyond one year.[ii]
NOTE: The Revivent Myocardial Anchoring System is approved for sale in Europe; it is not approved for sale in the United States. The Revivent-TC Ventricular Enhancement System requires regulatory approval and is not yet commercially available.
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 1-508-359-4005, x108